Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunitybio Inc (NQ: IBRX ) 3.550 +0.110 (+3.20%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immunitybio Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket September 12, 2024 Via Benzinga Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday September 09, 2024 Via Benzinga ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer September 09, 2024 From ImmunityBio, Inc. Via Business Wire How Is The Market Feeling About ImmunityBio? May 17, 2024 Via Benzinga Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga Top 3 Health Care Stocks That Are Set To Fly This Quarter August 16, 2024 Via Benzinga 9 Health Care Stocks Whale Activity In Today's Session August 13, 2024 Via Benzinga IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 August 12, 2024 IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval August 12, 2024 From ImmunityBio, Inc. Via Business Wire ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer August 06, 2024 From ImmunityBio, Inc. Via Business Wire IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX July 26, 2024 From Kahn Swick & Foti, LLC Via Business Wire 7 Biotech Stocks to Keep on Your Clinical Radar July 23, 2024 Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. Via InvestorPlace 3 Top Cancer Treatment Stocks to Buy Now July 17, 2024 These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. Via InvestorPlace China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? June 23, 2024 Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). Via Benzinga Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 20, 2024 Via Benzinga Why ImmunityBio Stock Is Trading Higher Thursday June 20, 2024 The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments. Via Benzinga KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday June 20, 2024 Via Benzinga ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors June 20, 2024 From ImmunityBio, Inc. Via Business Wire 3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions June 20, 2024 Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere. Via InvestorPlace 10 Health Care Stocks With Whale Alerts In Today's Session June 11, 2024 Via Benzinga ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update June 07, 2024 From ImmunityBio, Inc. Via Business Wire These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024 June 04, 2024 Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here. Via Talk Markets Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast May 17, 2024 From ImmunityBio, Inc. Via Business Wire Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months May 13, 2024 In the last three months, IBRX outperformed NVDA by over 3x. Via Talk Markets IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 May 10, 2024 IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace The 3 Best Bargain Stocks to Buy in May 2024 May 09, 2024 There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now. Via InvestorPlace Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday May 07, 2024 Via Benzinga ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® May 07, 2024 From ImmunityBio, Inc. Via Business Wire Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells May 06, 2024 Here are just a few of the top meme stocks to sell immediately. In fact, I wouldn't waste investment dollars on any. Via InvestorPlace Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy May 03, 2024 Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.